PlainMeds drug rankings
Most Adverse Event Reports
All tracked drugs ranked by total FDA adverse event reports filed through FAERS.
Data updated 2026-05-15
- 524
- Drugs ranked
- 695,825
- Top: Adalimumab
- 133,513
- #50: Citalopram
This board versus the other map
Ustekinumab is NADAC unit-cost #1 of 572 at $26,794.63/unit at FAERS #78 of 524 ≠ Adalimumab FAERS report-volume #1 of 524 at 695,825 at NADAC #8 of 572. Testosterone is a third map: recall-count #1 of 202 (28 actions).
- #1
- Ustekinumab NADAC
- $26,794.63
- per unit
- #1
- Adalimumab FAERS
- 695,825
- reports (not danger)
According to CMS NADAC and FDA FAERS compiled on /methodology. The table below is this board only. Report volume is not per-patient risk, and this page is not medical advice.
Verify with FDA → · CMS NADAC pricing →
What This Ranking Tells Us
The FDA Adverse Event Reporting System (FAERS) collects reports of adverse drug reactions from healthcare professionals, patients, and manufacturers. A high number of reports does not necessarily mean a drug is dangerous, widely prescribed drugs naturally accumulate more reports. Common over-the-counter medications like aspirin and acetaminophen often appear near the top due to massive usage volumes. Report counts should be interpreted relative to the number of patients taking the drug.
Top 12 by Total Reports
All tracked drugs ranked by total FDA adverse event reports filed through FAERS.
- adalimumab
adalimumab
695,825 Total Reports
- etanercept
etanercept
591,578 Total Reports
- aspirin
aspirin
518,554 Total Reports
- prednisone
prednisone
482,856 Total Reports
- acetaminophen
acetaminophen
417,458 Total Reports
- dupilumab
dupilumab
411,692 Total Reports
- methotrexate
methotrexate
410,053 Total Reports
- furosemide
furosemide
387,984 Total Reports
- ergocalciferol
ergocalciferol
366,491 Total Reports
- gabapentin
gabapentin
351,750 Total Reports
- metformin
metformin
342,023 Total Reports
- omeprazole
omeprazole
331,875 Total Reports
What this shows adalimumab leads at 695,825, ahead of etanercept and aspirin.
| # | Drug | Total Reports |
|---|---|---|
| 1 | adalimumab | 695,825 |
| 2 | etanercept | 591,578 |
| 3 | aspirin | 518,554 |
| 4 | prednisone | 482,856 |
| 5 | acetaminophen | 417,458 |
| 6 | dupilumab | 411,692 |
| 7 | methotrexate | 410,053 |
| 8 | furosemide | 387,984 |
| 9 | ergocalciferol | 366,491 |
| 10 | gabapentin | 351,750 |
| 11 | metformin | 342,023 |
| 12 | omeprazole | 331,875 |
| 13 | levothyroxine | 304,465 |
| 14 | lisinopril | 297,692 |
| 15 | dexamethasone | 285,895 |
| 16 | pregabalin | 264,092 |
| 17 | ibuprofen | 262,453 |
| 18 | amlodipine | 257,862 |
| 19 | metoprolol | 246,252 |
| 20 | simvastatin | 245,754 |
| 21 | folic acid | 241,433 |
| 22 | pantoprazole | 240,800 |
| 23 | atorvastatin | 240,204 |
| 24 | insulin glargine | 236,147 |
| 25 | infliximab | 211,136 |
| 26 | rivaroxaban | 203,269 |
| 27 | alprazolam | 200,719 |
| 28 | ranitidine | 197,405 |
| 29 | levonorgestrel | 197,074 |
| 30 | denosumab | 196,342 |
| 31 | rosuvastatin | 194,743 |
| 32 | clopidogrel | 192,921 |
| 33 | quetiapine | 185,533 |
| 34 | tofacitinib | 181,998 |
| 35 | oxycodone | 180,422 |
| 36 | adapalene | 178,147 |
| 37 | lorazepam | 174,469 |
| 38 | prednisolone | 173,227 |
| 39 | lansoprazole | 173,086 |
| 40 | losartan | 165,585 |
| 41 | secukinumab | 157,236 |
| 42 | clonazepam | 155,147 |
| 43 | evolocumab | 155,068 |
| 44 | allopurinol | 150,998 |
| 45 | apremilast | 143,174 |
| 46 | hydrochlorothiazide | 140,497 |
| 47 | escitalopram | 134,536 |
| 48 | insulin lispro | 134,198 |
| 49 | spironolactone | 133,996 |
| 50 | citalopram | 133,513 |
Primary source: FDA Adverse Event Reporting System (FAERS). Supplementary labeling: FDA Drug Labels (SPL). These rankings are source-record indexes and do not provide medical, treatment, substitution, or medication-change directions.
Frequently Asked Questions
What does a FAERS report mean?
A FAERS report documents a suspected adverse event associated with a drug. Reports come from healthcare providers, patients, lawyers, and drug manufacturers. A report does not prove the drug caused the event, it only documents a temporal association. FDA uses patterns across many reports to identify safety signals.
Why do common drugs have the most reports?
Drugs prescribed to millions of patients naturally accumulate more reports even if their individual risk is low. Aspirin, acetaminophen, and other widely used medications appear near the top because of sheer volume. A per-patient reporting rate would be more meaningful but is difficult to calculate from FAERS data alone.
What does a report-count ranking measure?
A report-count ranking orders the available FAERS records in this catalogue. It is not a per-patient rate, comparative safety score, or individual risk assessment.
Reading the Most Adverse Event Reports
This table ranks 50 drugs by total reports, sourced from FDA Adverse Event Reporting System (FAERS). The current leader is adalimumab at 695,825, followed by etanercept and aspirin. Each row links to a full drug profile so readers can move from headline number to the underlying FDA data, labeling, FAERS reports, recalls, pricing, and shortage status, that explains why a particular drug sits where it does.
The FDA Adverse Event Reporting System (FAERS) collects reports of adverse drug reactions from healthcare professionals, patients, and manufacturers. A high number of reports does not necessarily mean a drug is dangerous, widely prescribed drugs naturally accumulate more reports. Common over-the-counter medications like aspirin and acetaminophen often appear near the top due to massive usage volumes. Report counts should be interpreted relative to the number of patients taking the drug.
Rankings are diagnostic, not prescriptive. Absolute numbers are shaped by exposure volume, reporting practices, and data-collection methodology, so a drug near the top is not automatically "worse" than a drug near the bottom, it may simply be older, more widely prescribed, or manufactured by firms with more visible reporting. Context from FDA Adverse Event Reporting System (FAERS) updates continuously, which means the relative order here can change from one refresh to the next. Rankings on this page are for educational research only and must not be used as a substitute for medical advice from a licensed clinician.
Explore More Rankings
These rankings are for informational purposes only and do not constitute medical advice. They copy CMS NADAC and FDA FAERS/Enforcement Report extracts; they do not tell anyone which medicine to take. See methodology and guides.
Read our methodology - how this data is sourced, computed, and verified.
Source: FDA Adverse Event Reporting System (FAERS)
See our methodology for how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.